[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-344891-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-344891-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","pan-cancer-analysis-of-cldn3-and-its-contribution-to-5-fu-resistance-in-colorectal-cancer","Pan‐Cancer Analysis of CLDN3 and Its Contribution to 5-FU Resistance in Colorectal Cancer","","Expression patterns and regulatory correlates of CLDN3 across cancers are insufficiently characterized. Using R and bioinformatics platforms, aberrant CLDN3 expression was profiled, while in vitro assays in colorectal cancer assessed proliferation, wound healing, cell-cycle progression, and apoptosis. Co-immunoprecipitation and immunofluorescence tested CLDN3–TRIM28 association, and western blotting evaluated TRIM28 effects on CLDN3 SUMOylation and stability. Overexpression, genomic alterations, and promoter hypomethylation linked to dysregulation were found. CLDN3 knockdown reduced CRC growth and migration, whereas CLDN3 overexpression decreased 5-FU sensitivity. Results supported a TRIM28/CLDN3 axis as a therapeutic target via immune dysregulation and chemo-resistance mechanisms.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/pan-cancer-analysis-of-cldn3-and-its-contribution-to-5-fu-resistance-in-colorectal-cancer/344891/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/pan-cancer-analysis-of-cldn3-and-its-contribution-to-5-fu-resistance-in-colorectal-cancer/344891.png","ImageObject",300,407,{"name":42,"@type":43},"Ava Thompson","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main goal of the study regarding CLDN3?","Question",{"text":63,"@type":64},"To characterize CLDN3 expression patterns and regulatory correlates across cancers, and to determine how CLDN3 contributes to 5-FU resistance in colorectal cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the study evaluate the CLDN3–TRIM28 relationship?",{"text":68,"@type":64},"Co-immunoprecipitation and immunofluorescence were used to confirm a direct interaction between CLDN3 and TRIM28.",{"name":70,"@type":61,"acceptedAnswer":71},"What did TRIM28 do to CLDN3 and how did that affect treatment response?",{"text":72,"@type":64},"Western blotting showed that TRIM28 mediates CLDN3 SUMOylation and degradation; functionally, CLDN3 overexpression reduced CRC cell sensitivity to 5-FU, while CLDN3 knockdown decreased proliferation and migration.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},344891,1790879436,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1649267921044,"https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1786009248482753345","IET Systems Biology  \nORIGINAL RESEARCH  OPEN ACCESS   \nPan‐Cancer Analysis of CLDN3 and Its Contribution to 5‐FU Resistance in Colorectal Cancer  \nXi Zeng1,2 | Lu Zhang1,2 | Qing Chen1,3 | Yan Zeng1,4 | Guanglei Yang1,2 | Dan Feng1,2,5 | Bin Han1,2,4,6   \n1Department of Pharmacy, Affiliated Hospital of North Sichuan Medical College, Nanchong, China | 2Institute of Pharmacy, North Sichuan Medical College, Nanchong, China | 3Department of Gastroenterology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China | 4GCP Center/Institute of Drug Clinical Trials, Affiliated Hospital of North Sichuan Medical College, Nanchong, China | 5Anti‐Infective Agent Creation Engineering Research Centre of Sichuan Province, Sichuan Industrial Institute of Antibiotics, School of Pharmacy, Chengdu University, Chengdu, China | 6Biotechnology Innovation  \nDrug Application and Transformation Key Laboratory of Sichuan Province, North Sichuan Medical College, Nanchong, China Correspondence: Dan Feng ([binbinxinhao@163.com](binbinxinhao@163.com)) | Bin Han ([jarnihao@163.com](jarnihao@163.com))  \nReceived: 7 October 2025 | Revised: 9 February 2026 | Accepted: 19 February 2026  \nKeywords: bioinformatics | cancer | CLDN3  \nABSTRACT  \nThe expression patterns and potential regulatory correlates of CLDN3 in cancers remain insufficiently characterised, necessitating further investigation. We employed R software alongside bioinformatics platforms to analyse the aberrant expression of CLDN3 . Experiments in vitro, including proliferation, wound healing, cell cycle progression and apoptosis assays, were conducted to evaluate the role of CLDN3 in CRC. Co‐immunoprecipitation (CO‐IP) and immunofluorescence analyses were conducted to investigate the interaction between CLDN3 and TRIM28. Western blotting was employed to evaluate the effect of TRIM28 on CLDN3 SUMOylation and protein stability. CLDN3 was found to be overexpressed in several cancers. Genomic alterations and promoter hypomethylation were identified as key contributors to CLDN3 dysregulation. Bioinformatic analysis suggests that CLDN3 is associated with tumour progression and poor prognosis by influencing pathways, it also contributes to immune dysregulation and chemo‐resistance mechanisms. Knockdown of CLDN3 in CRC cells decreased proliferation and migration. CLDN3 overexpression was shown to reduce the sensitivity to 5‐FU in CRC cells. CO‐IP and immunofluorescence confirmed a direct interaction between CLDN3 and TRIM28 . Western blot analysis demonstrated that TRIM28 mediates CLDN3 SUMOylation and degradation. CLDN3 influences the growth and chemotherapy resistance of CRC cells, its interaction with TRIM28 makes the TRIM28/CLDN3 axis as a promising therapeutic target for CRC.  \n1 | Background  \nCancer is a major global public health issue with far‐reaching consequences for human health. In 2022, there were 20 million new cancer cases and 10 million cancer‐related deaths [1] . Alarmingly, these figures are expected to increase by 77% over the next 30 years compared to 2020 levels [1] . Despite significant advances in cancer diagnosis and treatment, the prognosis for many cancer types remains poor, primarily because of recurrence and metastasis. A factor contributing to  \nthis poor prognosis is epithelial‐mesenchymal transition (EMT), a process whereby tumour cells gain increased invasiveness, allowing them to infiltrate deeper tissues via the mucosa [2] . This invasive process is characterised by the disruption of various intercellular junctions, including tight junctions (TJs), adherens junctions, desmosomes and gap junctions between epithelial cells [3] . Among these, dysfunction of tight junctions plays a particularly critical role in cancer progression, although the precise molecular mechanisms underlying this process remain poorly understood [4] .  \n\n| Xi Zeng and Lu Zhang contributed equally to this work and share first authorship; Dan Feng and Bin Han have contributed equally to th","cbCaieTPP3m9vFiW","https://ap.wps.com/l/cbCaieTPP3m9vFiW","pdf",10811408,21,"English","# Background\n## CLDN3 and tight junction dysfunction in cancer\n## Rationale for pan-cancer and CRC mechanistic validation\n# Methods (bioinformatics and in vitro assays)\n## CLDN3 expression and dysregulation analyses\n## Interaction testing between CLDN3 and TRIM28\n## TRIM28-driven CLDN3 SUMOylation and stability evaluation\n# Results and implications\n## CLDN3 dysregulation, tumor progression, and prognosis\n## Effects of CLDN3 knockdown/overexpression on CRC phenotypes\n## TRIM28/CLDN3 axis and therapeutic targeting","[{\"question\":\"What was the main goal of the study regarding CLDN3?\",\"answer\":\"To characterize CLDN3 expression patterns and regulatory correlates across cancers, and to determine how CLDN3 contributes to 5-FU resistance in colorectal cancer.\"},{\"question\":\"How did the study evaluate the CLDN3–TRIM28 relationship?\",\"answer\":\"Co-immunoprecipitation and immunofluorescence were used to confirm a direct interaction between CLDN3 and TRIM28.\"},{\"question\":\"What did TRIM28 do to CLDN3 and how did that affect treatment response?\",\"answer\":\"Western blotting showed that TRIM28 mediates CLDN3 SUMOylation and degradation; functionally, CLDN3 overexpression reduced CRC cell sensitivity to 5-FU, while CLDN3 knockdown decreased proliferation and migration.\"}]","Pan‐Cancer Analysis of CLDN3 and Its Contribution to 5-FU Resistance in Colorectal Cancer | PDF",1790055611,53,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/189cd30e895a85b4a56c2a58c06b4cff.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1e2eb14cb29be8c6e44262a6739d7b18.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fb5c344491753a34ced7270c2bc141f3.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b39715b41eec11f6d61e91ebdf0e48e5.webp",980,1287]